Breaking News Instant updates and real-time market news.

BOLD

Audentes Therapeutics

$35.53

1.62 (4.78%)

07:01
01/04/18
01/04
07:01
01/04/18
07:01

Audentes Therapeutics reports 'positive' data from first dose cohort of ASPIRO

Audentes Therapeutics announced positive interim data from the first dose cohort of ASPIRO, a Phase 1/2 clinical trial of AT132 in patients with X-Linked Myotubular Myopathy. ASPIRO is a multicenter, multinational, open-label, ascending dose study to evaluate the safety and preliminary efficacy of AT132 in approximately 12 XLMTM patients less than five years of age. "The early AT132 efficacy data observed in our first dose cohort of patients have exceeded our expectations," stated Dr. Suyash Prasad, Senior Vice President and Chief Medical Officer of Audentes. "At the 12-week timepoint, Patient 1 has improved from a severely compromised baseline to achieve a CHOP-INTEND score and maximal inspiratory pressure that are approaching the ranges normally seen in healthy children. Importantly, Patient 1 has also attained several age-appropriate developmental milestones within this time period, including head-control, rolling over and sitting unassisted. While still early in the trial, we view these initial efficacy data as a promising indicator of the potential for AT132 to bring meaningful benefit to patients and families living with this devastating disease."

BOLD Audentes Therapeutics
$35.53

1.62 (4.78%)

11/15/17
LEER
11/15/17
NO CHANGE
Target $29
LEER
Outperform
Audentes Therapeutics price target raised to $29 from $22 at Leerink
Leerink analyst Joseph Schwartz raised his price target for Audentes Therapeutics to $29 from $22 saying it has made significant progress with upcoming catalysts for AT132 and AT342. Larger programs are also advancing towards IND filing, both of which are expected to occur in 2018, he adds. The analyst reiterates an Outperform rating on the shares.
12/05/17
BMOC
12/05/17
INITIATION
Target $35
BMOC
Outperform
Audentes Therapeutics initiated with an Outperform at BMO Capital
BMO Capital analyst Matthew Luchini started Audentes Therapeutics with an Outperform rating and $35 price target. The company is an "emerging" gene therapy company focused on treating rare diseases with few or no treatment options, the analyst tells investors in a research note. He believes its pipeline provides opportunities for long-term upside.
12/12/17
PIPR
12/12/17
NO CHANGE
Target $36
PIPR
Overweight
Audentes Therapeutics stock to run further on AT132 data, says Piper Jaffray
Piper Jaffray analyst Christopher Raymond assumed coverage of Audentes Therapeutics with an Overweight rating and a price target of $36. Raymond says that despite the 56% year-to-date price gain, shares are "poised for another leg higher" on initial human data on lead program AT132 next month and second program AT342 for Crigler Najjar starting to dose patients in its Phase 1/2 VALENS study in Q1 of 2018.
12/20/17
HCWC
12/20/17
INITIATION
Target $37
HCWC
Buy
Audentes Therapeutics initiated with a Buy at H.C. Wainwright
H.C. Wainwright analyst Debjit Chattopadhyay started Audentes Therapeutics with a Buy rating and $37 price target. The analyst views the company's market positioning in AAV-based gene therapy as compelling and believes 2018 is "catalyst-filled."

TODAY'S FREE FLY STORIES

FB

Facebook

$159.69

0.03 (0.02%)

05:28
04/26/18
04/26
05:28
04/26/18
05:28
Recommendations
Facebook analyst commentary  »

Facebook's strong Q1…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WELL

Welltower

$50.45

-0.57 (-1.12%)

, QCP

Quality Care Properties

$22.72

1.92 (9.23%)

05:25
04/26/18
04/26
05:25
04/26/18
05:25
Hot Stocks
Breaking Hot Stocks news story on Welltower, Quality Care Properties »

Welltower to acquire…

WELL

Welltower

$50.45

-0.57 (-1.12%)

QCP

Quality Care Properties

$22.72

1.92 (9.23%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    May

  • 03

    May

  • 04

    May

ANTM

Anthem

$238.81

13.73 (6.10%)

05:22
04/26/18
04/26
05:22
04/26/18
05:22
Upgrade
Anthem rating change  »

Anthem upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FB

Facebook

$159.69

0.03 (0.02%)

05:20
04/26/18
04/26
05:20
04/26/18
05:20
Recommendations
Facebook analyst commentary  »

Facebook price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ERN

Erin Energy

$1.65

-0.825 (-33.33%)

05:18
04/26/18
04/26
05:18
04/26/18
05:18
Hot Stocks
Erin Energy files voluntary petitions under Chapter 11 to pursue reorganization »

Erin Energy and certain…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CTXS

Citrix

$96.54

0.04 (0.04%)

05:16
04/26/18
04/26
05:16
04/26/18
05:16
Recommendations
Citrix analyst commentary  »

Citrix price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    May

  • 08

    May

  • 09

    May

AMD

AMD

$9.72

-0.37 (-3.67%)

05:13
04/26/18
04/26
05:13
04/26/18
05:13
Recommendations
AMD analyst commentary  »

AMD could see…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    May

EBAY

eBay

$40.98

-0.2 (-0.49%)

05:09
04/26/18
04/26
05:09
04/26/18
05:09
Recommendations
eBay analyst commentary  »

eBay GMV growth…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TRVG

Trivago

$4.71

-1.65 (-25.94%)

05:01
04/26/18
04/26
05:01
04/26/18
05:01
Downgrade
Trivago rating change  »

Trivago downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HPR

HighPoint Resources

$6.65

0.14 (2.15%)

04:58
04/26/18
04/26
04:58
04/26/18
04:58
Initiation
HighPoint Resources initiated  »

HighPoint Resources…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    May

AVY

Avery Dennison

$106.68

1.195 (1.13%)

04:57
04/26/18
04/26
04:57
04/26/18
04:57
Upgrade
Avery Dennison rating change  »

Avery Dennison upgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Apr

04:55
04/26/18
04/26
04:55
04/26/18
04:55
General news
Jobless Claims to be reported at 08:30 »

Week of 4/21 Jobless…

04:55
04/26/18
04/26
04:55
04/26/18
04:55
General news
Breaking General news story  »

Week of 4/25 Fed Balance…

04:55
04/26/18
04/26
04:55
04/26/18
04:55
General news
Durable Goods Orders to be reported at 08:30 »

March Durable Goods…

04:55
04/26/18
04/26
04:55
04/26/18
04:55
General news
Durable Goods Orders Ex-transportation to be reported at 08:30 »

March Durable Goods…

WYN

Wyndham

$117.67

1.83 (1.58%)

, LQ

La Quinta

$19.70

0.08 (0.41%)

04:55
04/26/18
04/26
04:55
04/26/18
04:55
Conference/Events
La Quinta to host special shareholder meeting »

Special Shareholder…

WYN

Wyndham

$117.67

1.83 (1.58%)

LQ

La Quinta

$19.70

0.08 (0.41%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Apr

  • 02

    May

04:55
04/26/18
04/26
04:55
04/26/18
04:55
General news
Wholesale Inventories [Advance] M/M % hange to be reported at 08:30 »

March Wholesale…

04:55
04/26/18
04/26
04:55
04/26/18
04:55
General news
International Trade in Goods Balance to be reported at 08:30 »

March International Trade…

04:55
04/26/18
04/26
04:55
04/26/18
04:55
General news
Breaking General news story  »

Week of 4/16 Money Supply…

04:55
04/26/18
04/26
04:55
04/26/18
04:55
General news
Breaking General news story  »

6-Month Bill Announcement…

04:55
04/26/18
04/26
04:55
04/26/18
04:55
General news
Breaking General news story  »

Week of 4/20 EIA Natural…

SMMT

Summit Therapeutics

$13.66

0.13 (0.96%)

04:55
04/26/18
04/26
04:55
04/26/18
04:55
Conference/Events
Summit Therapeutics management to meet with Needham »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Apr

  • 03

    May

ABBV

AbbVie

$91.91

0.57 (0.62%)

, ACOR

Acorda Therapeutics

$22.95

-0.15 (-0.65%)

04:55
04/26/18
04/26
04:55
04/26/18
04:55
Conference/Events
American Academy of Neurology to hold annual meeting »

2018 Annual Meeting of…

ABBV

AbbVie

$91.91

0.57 (0.62%)

ACOR

Acorda Therapeutics

$22.95

-0.15 (-0.65%)

ALXN

Alexion

$106.07

-0.37 (-0.35%)

AKCA

Akcea Therapeutics

$26.85

0.02 (0.07%)

RHHBY

Roche

TEVA

Teva

$17.27

-0.28 (-1.60%)

UBS

UBS

$16.78

-0.095 (-0.56%)

MDT

Medtronic

$79.47

0.12 (0.15%)

MCK

McKesson

$151.70

2.76 (1.85%)

NVTA

Invitae

$5.53

-0.15 (-2.64%)

IONS

Ionis Pharmaceuticals

$43.98

-1.35 (-2.98%)

IPXL

Impax

$19.25

-0.65 (-3.27%)

DNA

Bought by RHHBY

DGX

Quest Diagnostics

$101.17

1.42 (1.42%)

ESALY

Eisai

DEPO

Depomed

$6.66

-0.17 (-2.49%)

CPRX

Catalyst Pharmaceuticals

$2.64

0.04 (1.54%)

BSX

Boston Scientific

$29.44

1.01 (3.55%)

BMRN

BioMarin

$81.41

0.33 (0.41%)

MYL

Mylan

$38.93

-1.32 (-3.28%)

NBIX

Neurocrine

$78.13

-0.3 (-0.38%)

NVS

Novartis

$76.42

-0.58 (-0.75%)

PFE

Pfizer

$36.69

-0.36 (-0.97%)

RARX

RA Pharmaceuticals

$5.76

-0.2 (-3.36%)

SNY

Sanofi

$40.11

0.335 (0.84%)

SYK

Stryker

$165.44

0.77 (0.47%)

SUPN

Supernus

$47.30

0.55 (1.18%)

LLY

Eli Lilly

$81.17

1.08 (1.35%)

BAYRY

Bayer

AMGN

Amgen

$174.83

2.92 (1.70%)

ALNY

Alnylam

$94.35

-0.34 (-0.36%)

BIIB

Biogen

$269.47

7.45 (2.84%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Apr

  • 26

    Apr

  • 26

    Apr

  • 26

    Apr

  • 26

    Apr

  • 27

    Apr

  • 27

    Apr

  • 28

    Apr

  • 30

    Apr

  • 30

    Apr

  • 01

    May

  • 02

    May

  • 02

    May

  • 03

    May

  • 04

    May

  • 07

    May

  • 07

    May

  • 08

    May

  • 09

    May

  • 09

    May

  • 10

    May

  • 17

    May

  • 18

    May

  • 21

    May

  • 21

    May

  • 22

    May

  • 23

    May

  • 23

    May

  • 25

    May

  • 28

    May

  • 30

    May

  • 05

    Jun

  • 07

    Jun

  • 07

    Jun

  • 12

    Jun

  • 12

    Jun

  • 16

    Jun

  • 06

    Jul

  • 11

    Aug

  • 12

    Sep

  • 05

    Oct

  • 20

    Oct

  • 13

    Nov

  • 28

    Jan

SCPH

scPharmaceuticals

$9.92

-0.1 (-1.00%)

04:55
04/26/18
04/26
04:55
04/26/18
04:55
Conference/Events
scPharmaceuticals management to meet with Jefferies »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Apr

  • 23

    Jun

ALNA

Allena Pharmaceuticals

$14.77

0.845 (6.07%)

04:55
04/26/18
04/26
04:55
04/26/18
04:55
Conference/Events
Allena Pharmaceuticals management to meet with Jefferies »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Apr

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.